Literature DB >> 7113254

Pharmacokinetics and distribution of the new antihypertensive agent pinacidil in rat, dog and man.

E Eilertsen, J W Hart, M P Magnussen, H Sørensen, E Arrigoni-Martelli.   

Abstract

1. The antihypertensive agent pinacidil was rapidly, and almost completely, absorbed following oral administration of 0.5 mg/kg of the [14C]pinacidil monohydrate to rats and dogs. The half-life was about 1 and 2 h in the two species, respectively. A bioavailability of 80% of unchanged pinacidil in the rat suggests a first-pass effect in this species. 2. After oral and intravenous administration of [14C]pinacidil about 85% of the radioactivity was recovered in the urine and 15% in the faeces in rats and dogs; 80-90% was excreted during the first 24 h. Autoradiographic studies in the rat showed similar distributions after oral and intravenous administration. 3. An oral dose of 5 or 10 mg pinacidil monohydrate was rapidly absorbed in healthy volunteers and had a pharmacokinetic profile very similar to that found in rats and dogs. Concomitant food ingestion did not change the bioavailability of the drug.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7113254     DOI: 10.3109/00498258209046792

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  12 in total

Review 1.  Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H A Friedel; R N Brogden
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 2.  Pinacidil. Preclinical investigations.

Authors:  I Ahnfelt-Rønne
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Smooth muscle K+ channel openers; their pharmacology and clinical potential.

Authors:  A H Weston
Journal:  Pflugers Arch       Date:  1989       Impact factor: 3.657

4.  Variable metabolism of pinacidil: lack of correlation with the debrisoquine and trimethylamine C- and N-oxidative polymorphisms.

Authors:  R Ayesh; M Al-Waiz; A McBurney; S C Mitchell; J R Idle; J W Ward; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

5.  Serum concentrations and urinary excretion of pinacidil and its major metabolite, pinacidil pyridine-N-oxide following i.v. and oral administration in healthy volunteers.

Authors:  A McBurney; P R Farrow; S Ainsworth; J W Ward
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

6.  Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers.

Authors:  P Girard; J L Saumet; F Dubois; J P Boissel
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Pharmacokinetics and hypotensive effect in healthy volunteers of pinacidil, a new potent vasodilator.

Authors:  J W Ward; A McBurney; P R Farrow; P Sharp
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

8.  Pinacidil monotherapy for hypertension.

Authors:  J W Ward
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

9.  Pinacidil opens K+-selective channels causing hyperpolarization and relaxation of noradrenaline contractions in rat mesenteric resistance vessels.

Authors:  L M Videbaek; C Aalkjaer; M J Mulvany
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

10.  In vitro studies on the mode of action of pinacidil.

Authors:  A H Weston; K M Bray; S Duty; A D McHarg; D T Newgreen; J S Southerton
Journal:  Drugs       Date:  1988       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.